ROCK and JAK1 Signaling Cooperate to Control Actomyosin Contractility in Tumor Cells and Stroma

Cancer Cell

Volumn 20, Issue 2, 2011, Pages 229-245

  Sanz Moreno, Victoria ^a,e   Gaggioli, Cedric ^b,c   Yeo, Maggie ^a   Albrengues, Jean ^b,c   Wallberg, Fredrik ^a   Viros, Amaya ^d   Hooper, Steven ^d   Mitter, Richard ^d   Féral, Chloé C ^b,c   Cook, Martin ^f   Larkin, James ^g   Marais, Richard ^d   Meneguzzi, Guerrino ^b,c   Sahai, Erik ^d   Marshall, Chris J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSERM   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ENZYME INHIBITOR; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE INHIBITOR; MYOSIN ADENOSINE TRIPHOSPHATASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHOTRANSFERASE; PYRIDONE 6; RHO RHO KINASE; SD 1029; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STROMA CELL; TUMOR CELL;

EID: 80051587832     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.06.018     Document Type: Article

References (62)

1. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009, 15:425-430.
2. Aznar S., Valerón P.F., del Rincon S.V., Pérez L.F., Perona R., Lacal J.C. Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation. Mol. Biol. Cell 2001, 12:3282-3294.
3. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
4. Bromberg J., Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009, 15:79-80.
5. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
6. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernández-Luna J.L., Nuñez G., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
7. Chen S.H., Murphy D.A., Lassoued W., Thurston G., Feldman M.D., Lee W.M. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol. Ther. 2008, 7:1994-2003.
8. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
9. Croft D.R., Olson M.F. Conditional regulation of a ROCK-estrogen receptor fusion protein. Methods Enzymol. 2006, 406:541-553.
10. De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. J. Pathol. 2003, 200:429-447.
11. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147. Erratum: (2010). Cancer Cell 17, 523.
12. Friedl P., Wolf K. Proteolytic and non-proteolytic migration of tumour cells and leucocytes. Biochem. Soc. Symp. 2003, 70:277-285.
13. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3:362-374.
14. Friedl P., Wolf K. Plasticity of cell migration: a multiscale tuning model. J. Cell Biol. 2010, 188:11-19.
15. Gaemers I.C., Vos H.L., Volders H.H., van der Valk S.W., Hilkens J. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J. Biol. Chem. 2001, 276:6191-6199.
16. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9:1392-1400.
17. Gearing D.P., Comeau M.R., Friend D.J., Gimpel S.D., Thut C.J., McGourty J., Brasher K.K., King J.A., Gillis S., Mosley B., et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992, 255:1434-1437.
18. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
19. Grinnell F. Fibroblast biology in three-dimensional collagen matrices. Trends Cell Biol. 2003, 13:264-269.
20. Grivennikov S.I., Karin M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 2010, 20:65-71.
21. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
22. Guilluy C., Brégeon J., Toumaniantz G., Rolli-Derkinderen M., Retailleau K., Loufrani L., Henrion D., Scalbert E., Bril A., Torres R.M., et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat. Med. 2010, 16:183-190.
23. Hooper S., Gaggioli C., Sahai E. A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion. Br. J. Cancer 2010, 102:392-402.
24. Ito M., Nakano T., Erdodi F., Hartshorne D.J. Myosin phosphatase: structure, regulation and function. Mol. Cell. Biochem. 2004, 259:197-209.
25. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., Yoshida K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2006, 25:1195-1204.
26. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
27. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., Massagué J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
28. Liu K.D., Gaffen S.L., Goldsmith M.A., Greene W.C. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr. Biol. 1997, 7:817-826.
29. Melnikova V.O., Bar-Eli M. Inflammation and melanoma metastasis. Pigment Cell Melanoma Res. 2009, 22:257-267.
30. Meshel A.S., Wei Q., Adelstein R.S., Sheetz M.P. Basic mechanism of three-dimensional collagen fibre transport by fibroblasts. Nat. Cell Biol. 2005, 7:157-164.
31. Moretti S., Pinzi C., Spallanzani A., Berti E., Chiarugi A., Mazzoli S., Fabiani M., Vallecchi C., Herlyn M. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int. J. Cancer 1999, 84:160-168.
32. Mozaffarian A., Brewer A.W., Trueblood E.S., Luzina I.G., Todd N.W., Atamas S.P., Arnett H.A. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J. Immunol. 2008, 181:7243-7253.
33. Ng G., Winder D., Muralidhar B., Gooding E., Roberts I., Pett M., Mukherjee G., Huang J., Coleman N. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. J. Pathol. 2007, 212:325-334.
34. Nightingale J., Patel S., Suzuki N., Buxton R., Takagi K.I., Suzuki J., Sumi Y., Imaizumi A., Mason R.M., Zhang Z. Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. J. Am. Soc. Nephrol. 2004, 15:21-32.
35. O'Brien C.A., Manolagas S.C. Isolation and characterization of the human gp130 promoter. Regulation by STATS. J. Biol. Chem. 1997, 272:15003-15010.
36. O'Shea J.J., Gadina M., Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002, 109(Suppl):S121-S131.
37. Pedranzini L., Leitch A., Bromberg J. Stat3 is required for the development of skin cancer. J. Clin. Invest. 2004, 114:619-622.
38. Pedranzini L., Dechow T., Berishaj M., Comenzo R., Zhou P., Azare J., Bornmann W., Bromberg J. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006, 66:9714-9721.
39. Pinner S., Sahai E. Imaging amoeboid cancer cell motility in vivo. J. Microsc. 2008, 231:441-445.
40. Pinner S., Jordan P., Sharrock K., Bazley L., Collinson L., Marais R., Bonvin E., Goding C., Sahai E. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 2009, 69:7969-7977.
41. Provenzano P.P., Eliceiri K.W., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006, 4:38.
42. Radisky D.C., Kenny P.A., Bissell M.J. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?. J. Cell. Biochem. 2007, 101:830-839.
43. Rose-John S., Waetzig G.H., Scheller J., Grötzinger J., Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets 2007, 11:613-624.
44. Sahai E., Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 2003, 5:711-719.
45. Salguero G., Schuett H., Jagielska J., Schley R., Tallone E., Luchtefeld M., Drexler H., Müller W., Grote K., Schieffer B. Hepatocyte gp130 deficiency reduces vascular remodeling after carotid artery ligation. Hypertension 2009, 54:1035-1042.
46. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., Sahai E., Marshall C.J. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
47. Snyder M., Huang X.Y., Zhang J.J. Identification of novel direct Stat3 target genes for control of growth and differentiation. J. Biol. Chem. 2008, 283:3791-3798.
48. Song Y., Qian L., Song S., Chen L., Zhang Y., Yuan G., Zhang H., Xia Q., Hu M., Yu M., et al. Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. Mol. Immunol. 2008, 45:137-143.
49. Straight A.F., Cheung A., Limouze J., Chen I., Westwood N.J., Sellers J.R., Mitchison T.J. Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor. Science 2003, 299:1743-1747.
50. Thompson J.E., Cubbon R.M., Cummings R.T., Wicker L.S., Frankshun R., Cunningham B.R., Cameron P.M., Meinke P.T., Liverton N., Weng Y., DeMartino J.A. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12:1219-1223.
51. van Kempen L.C., Ruiter D.J., van Muijen G.N., Coussens L.M. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur. J. Cell Biol. 2003, 82:539-548.
52. Viros A., Fridlyand J., Bauer J., Lasithiotakis K., Garbe C., Pinkel D., Bastian B.C. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008, 5:e120.
53. Wilkinson S., Paterson H.F., Marshall C.J. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat. Cell Biol. 2005, 7:255-261.
54. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., Strongin A.Y., Bröcker E.B., Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160:267-277.
55. Wyckoff J.B., Pinner S.E., Gschmeissner S., Condeelis J.S., Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr. Biol. 2006, 16:1515-1523.
56. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560.
57. Xiong H., Zhang Z.G., Tian X.Q., Sun D.F., Liang Q.C., Zhang Y.J., Lu R., Chen Y.X., Fang J.Y. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008, 10:287-297.
58. Yakata Y., Nakayama T., Yoshizaki A., Kusaba T., Inoue K., Sekine I. Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int. J. Oncol. 2007, 30:437-442.
59. Yamaoka K., Saharinen P., Pesu M., Holt V.E., Silvennoinen O., O'Shea J.J. The Janus kinases (Jaks). Genome Biol. 2004, 5:253.
60. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
61. Yue P., Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin. Investig. Drugs 2009, 18:45-56.
62. Zhao S., Venkatasubbarao K., Lazor J.W., Sperry J., Jin C., Cao L., Freeman J.W. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res. 2008, 68:4221-4228.